“Early and Sustained Treatment Satisfaction Observed in Patients With Moderate to Severe Psoriasis Treated With Ixekizumab: Results From Second Interim Analysis of the Real-World Psoriasis in Special Areas (PSoSA) Study” (2025) SKIN The Journal of Cutaneous Medicine, 9(1), p. s509. doi:10.25251/skin.9.supp.509.